Soluble epoxide hydrolase inhibition is antinociceptive in a mouse model of diabetic neuropathy

Journal of Pain

Volumn 15, Issue 9, 2014, Pages 907-914

  Wagner, Karen ^a   Yang, Jun ^a   Inceoglu, Bora ^a   Hammock, Bruce D ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

antihyperalgesia; conditioned place preference; epoxy fatty acids; Neuropathic pain; soluble epoxide hydrolase

Indexed keywords

4 [4 (3 TRIFLUOROMETHOXYPHENYL 1 UREIDO)CYCLOHEXYLOXY]BENZOIC ACID; ANALGESIC AGENT; EPOXIDE HYDROLASE; FATTY ACID; GABAPENTIN; MORPHINE; UC 1728; UNCLASSIFIED DRUG; 4 AMINOBUTYRIC ACID; 4-(4-(3-(4-TRIFLUOROMETHOXY-PHENYL)UREIDO)CYCLOHEXYLOXY)BENZOIC ACID; AMINE; BENZOIC ACID DERIVATIVE; CARBANILAMIDE DERIVATIVE; CYCLOHEXANECARBOXYLIC ACID DERIVATIVE; ENZYME INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINOCICEPTION; CHRONIC PAIN; CONDITIONED PLACE PREFERENCE TEST; CONTROLLED STUDY; DRUG EFFICACY; ENZYME INHIBITION; EXPERIMENTAL DIABETIC NEUROPATHY; INFLAMMATORY PAIN; LOCOMOTION; MALE; MOUSE; NEUROPATHIC PAIN; NONHUMAN; REINFORCEMENT; REVIEW; REWARD; SINGLE DRUG DOSE; 129 MOUSE; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; C57BL MOUSE; COMPARATIVE STUDY; CONDITIONING; DEPTH PERCEPTION; DIABETIC NEUROPATHIES; DOSE RESPONSE; DRUG EFFECTS; EXPERIMENTAL DIABETES MELLITUS; GENETICS; KNOCKOUT MOUSE; MOTOR ACTIVITY; NEURALGIA; NOCICEPTIVE PAIN; PAIN THRESHOLD; PATHOPHYSIOLOGY;

AMINES; ANALGESICS; ANIMALS; BENZOATES; CHRONIC PAIN; CONDITIONING (PSYCHOLOGY); CYCLOHEXANECARBOXYLIC ACIDS; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEUROPATHIES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; EPOXIDE HYDROLASES; GAMMA-AMINOBUTYRIC ACID; MALE; MICE, 129 STRAIN; MICE, INBRED C57BL; MICE, KNOCKOUT; MOTOR ACTIVITY; NEURALGIA; NOCICEPTIVE PAIN; PAIN THRESHOLD; PHENYLUREA COMPOUNDS; SPACE PERCEPTION;

EID: 84906934941     PISSN: 15265900     EISSN: 15288447     Source Type: Journal    
DOI: 10.1016/j.jpain.2014.05.008     Document Type: Article

References (38)

1. M.M. Backonja, and B. Stacey Neuropathic pain symptoms relative to overall pain rating J Pain 5 2004 491 497
2. M.T. Bardo, and R.A. Bevins Conditioned place preference: What does it add to our preclinical understanding of drug reward? Psychopharmacology (Berl) 153 2000 31 43
3. G. Blackburn-Munro, and H.K. Erichsen Antiepileptics and the treatment of neuropathic pain: Evidence from animal models Curr Pharm Des 11 2005 2961 2976
4. A.J. Boulton, A.I. Vinik, J.C. Arezzo, V. Bril, E.L. Feldman, R. Freeman, R.A. Malik, R.E. Maser, J.M. Sosenko, and D. Ziegler Diabetic neuropathies: A statement by the American Diabetes Association Diabetes Care 28 2005 956 962
5. G.D. Carr, H.C. Fibiger, and A.G. Phillips Conditioned place preference as a measure of drug reward J.M. Liebman, S.J. Cooper, The Neuropharmacological Basis of Reward 1989 Clarendon Press Oxford 264 319
6. G.D. Carr, and N.M. White Conditioned place preference from intra-accumbens but not intra-caudate amphetamine injections Life Sci 33 1983 2551 2557
7. J.L. Conroy, C. Fang, J. Gu, S.O. Zeitlin, W. Yang, J. Yang, M.A. VanAlstine, J.W. Nalwalk, P.J. Albrecht, J.E. Mazurkiewicz, A. Snyder-Keller, Z. Shan, S.-Z. Zhang, M.P. Wentland, M. Behr, B.I. Knapp, J.M. Bidlack, O.P. Zuiderveld, R. Leurs, X. Ding, and L.B. Hough Opioids activate brain analgesic circuits through cytochrome P450/epoxygenase signaling Nat Neurosci 13 2010 284 286
8. G. Danaei, M.M. Finucane, Y. Lu, G.M. Singh, M.J. Cowan, C.J. Paciorek, J.K. Lin, F. Farzadfar, Y.H. Khang, G.A. Stevens, M. Rao, M.K. Ali, L.M. Riley, C.A. Robinson, and M. Ezzati National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: Systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants Lancet 378 2011 31 40
9. E. Davidson, L. Coppey, B. Lu, V. Arballo, N.A. Calcutt, C. Gerard, and M. Yorek The roles of streptozotocin neurotoxicity and neutral endopeptidase in murine experimental diabetic neuropathy Exp Diabetes Res 2009 2009 Article ID 431980
10. L. Davoody, R.L. Quiton, J.M. Lucas, Y. Ji, A. Keller, and R. Masri Conditioned place preference reveals tonic pain in an animal model of central pain J Pain 12 2011 868 874
11. A. Di Lio, D. Benke, M. Besson, J. Desmeules, Y. Daali, Z.J. Wang, R. Edwankar, J.M. Cook, and H.U. Zeilhofer HZ166, a novel GABAA receptor subtype-selective benzodiazepine site ligand, is antihyperalgesic in mouse models of inflammatory and neuropathic pain Neuropharmacology 60 2011 626 632
12. J.L. Edwards, A.M. Vincent, H.T. Cheng, and E.L. Feldman Diabetic neuropathy: Mechanisms to management Pharmacol Ther 120 2008 1 34
13. A.G.P. Guedes, C. Morisseau, A. Sole, J.H.N. Soares, A. Ulu, H. Dong, and B.D. Hammock Use of a soluble epoxide hydrolase inhibitor as an adjunctive analgesic in a horse with laminitis Vet Anaesth Analg 40 2013 440 448
14. S.H. Hwang, H.J. Tsai, J.Y. Liu, C. Morisseau, and B.D. Hammock Orally bioavailable potent soluble epoxide hydrolase inhibitors J Med Chem 50 2007 3825 3840
15. B. Inceoglu, S.L. Jinks, K.R. Schmelzer, T. Waite, I.H. Kim, and B.D. Hammock Inhibition of soluble epoxide hydrolase reduces LPS-induced thermal hyperalgesia and mechanical allodynia in a rat model of inflammatory pain Life Sci 79 2006 2311 2319
16. B. Inceoglu, S.L. Jinks, A. Ulu, C.M. Hegedus, K. Georgi, K.R. Schmelzer, K. Wagner, P.D. Jones, C. Morisseau, and B.D. Hammock Soluble epoxide hydrolase and epoxyeicosatrienoic acids modulate two distinct analgesic pathways Proc Natl Acad Sci U S A 105 2008 18901 18906
17. T. King, L. Vera-Portocarrero, T. Gutierrez, T.W. Vanderah, G. Dussor, J. Lai, H.L. Fields, and F. Porreca Unmasking the tonic-aversive state in neuropathic pain Nat Neurosci 12 2009 1364 1366
18. T. Kiso, T. Watabiki, M. Tsukamoto, M. Okabe, M. Kagami, K. Nishimura, T. Aoki, and N. Matsuoka Pharmacological characterization and gene expression profiling of an L5/L6 spinal nerve ligation model for neuropathic pain in mice Neuroscience 153 2008 492 500
19. S. Kundu, T. Roome, A. Bhattacharjee, K.A. Carnevale, V.P. Yakubenko, R. Zhang, S.H. Hwang, B.D. Hammock, and M.K. Cathcart Metabolic products of soluble epoxide hydrolase are essential for monocyte chemotaxis to MCP-1 in vitro and in vivo J Lipid Res 54 2013 436 447
20. N. Kusunose, S. Koyanagi, K. Hamamura, N. Matsunaga, M. Yoshida, T. Uchida, M. Tsuda, K. Inoue, and S. Ohdo Molecular basis for the dosing time-dependency of anti-allodynic effects of gabapentin in a mouse model of neuropathic pain Mol Pain 6 2010 83
21. A. Latremoliere, and C.J. Woolf Central sensitization: A generator of pain hypersensitivity by central neural plasticity J Pain 10 2009 895 926
22. J.Y. Liu, Y.P. Lin, H. Qiu, C. Morisseau, T.E. Rose, S.H. Hwang, N. Chiamvimonvat, and B.D. Hammock Substituted phenyl groups improve the pharmacokinetic profile and anti-inflammatory effect of urea-based soluble epoxide hydrolase inhibitors in murine models Eur J Pharmaceutical Sci 48 2013 619 627
23. J.Y. Liu, H.J. Tsai, S.H. Hwang, P.D. Jones, C. Morisseau, and B.D. Hammock Pharmacokinetic optimization of four soluble epoxide hydrolase inhibitors for use in a murine model of inflammation Br J Pharmacol 156 2009 284 296
24. A. Luria, C. Morisseau, H.J. Tsai, J. Yang, B. Inceoglu, B. De Taeye, S.M. Watkins, M.M. Wiest, J.B. German, and B.D. Hammock Alteration in plasma testosterone levels in male mice lacking soluble epoxide hydrolase Am J Physiol Endocrinol Metab 297 2009 E375 E383
25. J.S. Mogil Animal models of pain: Progress and challenges Nat Rev Neurosci 10 2009 283 294
26. C. Morisseau, B. Inceoglu, K. Schmelzer, H.J. Tsai, S.L. Jinks, C.M. Hegedus, and B.D. Hammock Naturally occurring monoepoxides of eicosapentaenoic acid and docosahexaenoic acid are bioactive antihyperalgesic lipids J Lipid Res 51 2010 3481 3490
27. R.F. Mucha, D. van der Kooy, M. O'Shaughnessy, and P. Bucenieks Drug reinforcement studied by the use of place conditioning in rat Brain Res 243 1982 91 105
28. H.J. Park, J.A. Stokes, E. Pirie, J. Skahen, Y. Shtaerman, and T.L. Yaksh Persistent hyperalgesia in the cisplatin-treated mouse as defined by threshold measures, the conditioned place preference paradigm, and changes in dorsal root ganglia activated transcription factor 3: The effects of gabapentin, ketorolac, and etanercept Anesth Analg 116 2013 224 231
29. L. Prut, and C. Belzung The open field as a paradigm to measure the effects of drugs on anxiety-like behaviors: A review Eur J Pharmacol 463 2003 3 33
30. C.J. Sinal, M. Miyata, M. Tohkin, K. Nagata, J.R. Bend, and F.J. Gonzalez Targeted disruption of soluble epoxide hydrolase reveals a role in blood pressure regulation J Biol Chem 275 2000 40504 40510
31. K.E. Stevens, G.A. Mickley, and L.J. McDermott Brain areas involved in production of morphine-induced locomotor hyperactivity of the C57B1/6J mouse Pharmacol Biochem Behav 24 1986 1739 1747
32. K.J. Sufka Conditioned place preference paradigm: A novel approach for analgesic drug assessment against chronic pain Pain 58 1994 355 366
33. K.J. Sufka Translational challenges and analgesic screening assays Pain 152 2011 1942 1943
34. M. Terashvili, L.F. Tseng, H.E. Wu, J. Narayanan, L.M. Hart, J.R. Falck, P.F. Pratt, and D.R. Harder Antinociception produced by 14,15- epoxyeicosatrienoic acid is mediated by the activation of beta-endorphin and met-enkephalin in the rat ventrolateral periaqueductal gray J Pharmacol Exp Ther 326 2008 614 622
35. M.A. Tomić, S.M. Vučković, R.M. Stepanović- Petrović, A.M. Micov, N.D. Ugrešić, M.Š. Prostran, and B. Bošković Analysis of the antinociceptive interactions in two-drug combinations of gabapentin, oxcarbazepine and amitriptyline in streptozotocin-induced diabetic mice Eur J Pharmacol 628 2010 75 82
36. T.M. Tzschentke Measuring reward with the conditioned place preference (CPP) paradigm: Update of the last decade Addict Biol 12 2007 227 462
37. A. Ulu, B.B. Davis, H.J. Tsai, I.H. Kim, C. Morisseau, B. Inceoglu, O. Fiehn, B.D. Hammock, and R.H. Weiss Soluble epoxide hydrolase inhibitors reduce the development of atherosclerosis in apolipoprotein e-knockout mouse model J Cardiovasc Pharmacol 52 2008 314 323
38. K. Wagner, B. Inceoglu, H. Dong, J. Yang, S.H. Hwang, P. Jones, C. Morisseau, and B.D. Hammock Comparative efficacy of 3 soluble epoxide hydrolase inhibitors in rat neuropathic and inflammatory pain models Eur J Pharmacol 700 2013 93 101